Concepedia

Ann Mariën

AM

Statistics

Publications

6

Citations

212

H-Index

6

Active since

2005

Affiliations

Johnson & Johnson (United States)(Current)

Janssen (United States)

Janssen (Belgium)

University Medical Center Groningen

University of Groningen

Ann Mariën is an author at Johnson & Johnson (United States) specializing in pharmacology, cancer pharmacology, and histone deacetylases.

Publications per year

2005–2024

6

Publications

6

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

Janine Arts, Patrick Angibaud, Ann Mariën et al. · British Journal of Cancer · 2007 · 89 citations · Full text

, , +15

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias

Min Chul Kwon, Jan Willem Thuring, Olivier Querolle et al. · Blood · 2024 · 59 citations · Full text

, , +4

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors

Patrick Angibaud, Kristof Van Emelen, Laurence Decrane et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 18 citations · Full text

, , +9

Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors

Patrick Angibaud, Janine Arts, Kristof Van Emelen et al. · European Journal of Medicinal Chemistry · 2005 · 16 citations

, , +11

Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

Min Chul Kwon, Olivier Querolle, Xuedong Dai et al. · Blood · 2022 · 16 citations

, , +9

1–5 of 6